Furthermore, we confirmed that inhibition of AP-1 activity and senolytic therapies reduce progression of inflammation and fibrosis following experimental AKI and warrant further research as a treatment to prevent AKI to CKD transition and progression of CKD in patients with kidney disease. This evidence concerns the gene JUN and kidney disorder.